# Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

> **NCT05297617** · PHASE2 · RECRUITING · sponsor: **UNICANCER** · enrollment: 696 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anti-aromatase inhibitor

## Key facts

- **NCT ID:** NCT05297617
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2030-11-12
- **Final completion:** 2035-11
- **Target enrollment:** 696 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297617, "Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05297617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*